<DOC>
	<DOC>NCT01148810</DOC>
	<brief_summary>This study will determine the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients that are not responsive to traditional immunosuppressive and/or corticosteroid therapy. The study will consist of a 12 week, randomized, placebo controlled period, followed by another 12 weeks where all subjects will receive BAF312 treatment.</brief_summary>
	<brief_title>Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<criteria>Patients with disease at least 3 months before study Muscle weakness Received corticosteroids with or with out disease modifying antirheumatic drugs at least 3 months before study however not responding to this therapy Other idiopathic inflammatory myopathies Myopathy other than polymyositis and dermatomyositis Patients with late stages of disease Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Inflammatory muscle disease</keyword>
	<keyword>Muscle weakness</keyword>
	<keyword>Myositis</keyword>
</DOC>